SG11202108619SA - Tyk2 pseudokinase ligands - Google Patents
Tyk2 pseudokinase ligandsInfo
- Publication number
- SG11202108619SA SG11202108619SA SG11202108619SA SG11202108619SA SG11202108619SA SG 11202108619S A SG11202108619S A SG 11202108619SA SG 11202108619S A SG11202108619S A SG 11202108619SA SG 11202108619S A SG11202108619S A SG 11202108619SA SG 11202108619S A SG11202108619S A SG 11202108619SA
- Authority
- SG
- Singapore
- Prior art keywords
- ligands
- tyk2 pseudokinase
- tyk2
- pseudokinase ligands
- pseudokinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962802642P | 2019-02-07 | 2019-02-07 | |
| PCT/US2020/017314 WO2020163778A1 (fr) | 2019-02-07 | 2020-02-07 | Ligands de pseudokinase tyk2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202108619SA true SG11202108619SA (en) | 2021-09-29 |
Family
ID=71947508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202108619SA SG11202108619SA (en) | 2019-02-07 | 2020-02-07 | Tyk2 pseudokinase ligands |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220135567A1 (fr) |
| EP (1) | EP3920931A4 (fr) |
| JP (1) | JP2022519696A (fr) |
| KR (1) | KR20210124409A (fr) |
| CN (1) | CN113677347A (fr) |
| AU (1) | AU2020218267A1 (fr) |
| BR (1) | BR112021015616A2 (fr) |
| CA (1) | CA3129438A1 (fr) |
| IL (1) | IL285429A (fr) |
| MX (1) | MX2021009555A (fr) |
| SG (1) | SG11202108619SA (fr) |
| WO (1) | WO2020163778A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202104017VA (en) | 2018-10-22 | 2021-05-28 | Esker Therapeutics Inc | Tyk2 inhibitors and uses thereof |
| KR20220004641A (ko) | 2019-03-26 | 2022-01-11 | 벤틱스 바이오사이언스, 인크. | Tyk2 슈도키나아제 리간드 |
| AU2020378345A1 (en) | 2019-11-08 | 2022-06-02 | Ventyx Biosciences, Inc. | TYK2 pseudokinase ligands |
| EP4214215A1 (fr) * | 2020-09-16 | 2023-07-26 | Alumis Inc. | Inhibiteurs de tyk2 et leurs utilisations |
| US20240335443A1 (en) * | 2021-01-19 | 2024-10-10 | Anrui Biomedical Technology (Guangzhou) Co., Ltd. | Imidazolopyridazine or pyrazolopyrimidine compounds and compositions |
| KR20240111312A (ko) | 2021-10-25 | 2024-07-16 | 카이메라 쎄라퓨틱스 인코포레이티드 | Tyk2 분해제 및 이의 용도 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4564485B2 (ja) * | 2003-02-28 | 2010-10-20 | 帝人ファーマ株式会社 | ピラゾロ［１，５−ａ］ピリミジン誘導体 |
| TW201720828A (zh) * | 2015-11-23 | 2017-06-16 | 赫孚孟拉羅股份公司 | 治療性化合物及組合物以及其使用方法 |
| EP4338802A3 (fr) * | 2017-03-08 | 2024-09-04 | Takeda Pharmaceutical Company Limited | Inhibiteurs de tyk2, utilisations et procédés de production associés |
| CN110678467B (zh) * | 2017-05-22 | 2023-06-13 | 豪夫迈·罗氏有限公司 | 治疗化合物和组合物及其使用方法 |
| JP7216705B2 (ja) * | 2017-07-28 | 2023-02-02 | ニンバス ラクシュミ， インコーポレイテッド | Ｔｙｋ２阻害剤およびその使用方法 |
| JP7179161B2 (ja) * | 2018-09-10 | 2022-11-28 | イーライ リリー アンド カンパニー | 乾癬および全身性エリテマトーデスの処置に有用なピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミド誘導体 |
| JP2022502515A (ja) * | 2018-10-15 | 2022-01-11 | ニンバス ラクシュミ， インコーポレイテッド | Ｔｙｋ２阻害剤およびその使用 |
| AR117177A1 (es) * | 2018-12-10 | 2021-07-14 | Lilly Co Eli | DERIVADOS DE 7-(METILAMINO)PIRAZOLO[1,5-A]PIRIMIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE IL-23 E INFa |
-
2020
- 2020-02-07 CN CN202080026979.3A patent/CN113677347A/zh active Pending
- 2020-02-07 SG SG11202108619SA patent/SG11202108619SA/en unknown
- 2020-02-07 US US17/428,953 patent/US20220135567A1/en active Pending
- 2020-02-07 MX MX2021009555A patent/MX2021009555A/es unknown
- 2020-02-07 WO PCT/US2020/017314 patent/WO2020163778A1/fr unknown
- 2020-02-07 JP JP2021546005A patent/JP2022519696A/ja active Pending
- 2020-02-07 CA CA3129438A patent/CA3129438A1/fr active Pending
- 2020-02-07 AU AU2020218267A patent/AU2020218267A1/en active Pending
- 2020-02-07 KR KR1020217028660A patent/KR20210124409A/ko unknown
- 2020-02-07 BR BR112021015616A patent/BR112021015616A2/pt unknown
- 2020-02-07 EP EP20752194.9A patent/EP3920931A4/fr active Pending
-
2021
- 2021-08-08 IL IL285429A patent/IL285429A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022519696A (ja) | 2022-03-24 |
| CA3129438A1 (fr) | 2020-08-13 |
| WO2020163778A1 (fr) | 2020-08-13 |
| EP3920931A4 (fr) | 2022-08-10 |
| KR20210124409A (ko) | 2021-10-14 |
| BR112021015616A2 (pt) | 2021-11-09 |
| MX2021009555A (es) | 2021-10-13 |
| US20220135567A1 (en) | 2022-05-05 |
| AU2020218267A1 (en) | 2021-09-30 |
| IL285429A (en) | 2021-09-30 |
| EP3920931A1 (fr) | 2021-12-15 |
| CN113677347A (zh) | 2021-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286635A (en) | tyk2 pseudokinase ligands | |
| IL285429A (en) | tyk2 pseudokinase ligands | |
| ZA202100442B (en) | Bicyclic peptide ligands specific for nectin-4 | |
| GB202013426D0 (en) | No Details | |
| EP4054581A4 (fr) | Ligands de pseudokinase tyk2 | |
| GB202009212D0 (en) | No details | |
| GB202017837D0 (en) | No details | |
| EP3766640C0 (fr) | Pied magnétique | |
| IL285791A (en) | Intent-driven communication center | |
| EP3997086C0 (fr) | Composés de tétrahydroisoquinoline | |
| GB202015405D0 (en) | No details | |
| IL288378A (en) | Biomolecules are radioactively labeled with 18f | |
| IL288304A (en) | Disc pump | |
| GB201900566D0 (en) | Carrier | |
| GB202006205D0 (en) | No details | |
| GB202014354D0 (en) | No details | |
| GB201820320D0 (en) | Bicyclic peptide ligands specific for FAPalpha | |
| PL3845343T3 (pl) | Podstawa magnetyczna | |
| GB201903058D0 (en) | Adsorption | |
| GB201913937D0 (en) | Ligand Design | |
| GB201904518D0 (en) | Uvvyowgbrir circular | |
| GB201918871D0 (en) | Complexes | |
| GB201810321D0 (en) | Peptide ligands for bindingto EphA2 | |
| GB201911303D0 (en) | Moleculaer complexes | |
| GB202009827D0 (en) | Carrier |